Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24082
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Coles, A. J. | - |
dc.contributor.author | Boyko, A. N. | - |
dc.contributor.author | Cohen, J. A. | - |
dc.contributor.author | De Seze, J. | - |
dc.contributor.author | Fox, E. J. | - |
dc.contributor.author | Havrdova, E. | - |
dc.contributor.author | Hartung, H. -P. | - |
dc.contributor.author | Inshasi, J. S. | - |
dc.contributor.author | McCombe, P. | - |
dc.contributor.author | Selmaj, K. W. | - |
dc.contributor.author | Vermersch, P. | - |
dc.contributor.author | VAN WIJMEERSCH, Bart | - |
dc.contributor.author | Margolin, D. H. | - |
dc.contributor.author | Thangavelu, K. | - |
dc.contributor.author | Rodriguez, C. E. | - |
dc.contributor.author | Montalban, X. | - |
dc.date.accessioned | 2017-08-04T13:45:21Z | - |
dc.date.available | 2017-08-04T13:45:21Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | MULTIPLE SCLEROSIS JOURNAL, 22, p. 75-76 (Art N° 213) | - |
dc.identifier.issn | 1352-4585 | - |
dc.identifier.uri | http://hdl.handle.net/1942/24082 | - |
dc.description.sponsorship | Sanofi Genzyme and Bayer HealthCare Pharmaceuticals. AJC: Consulting fees, lecture fees, and institutional grant support (Sanofi Genzyme). ANB: Consulting fees/participated in clinical trials (Bayer, Biogen, Merck Serono, Novartis, Sanofi-Aventis, Sanofi Genzyme, and Teva Pharmaceuticals). JAC: Consulting and/or speaking fees (Genentech, Novartis, Sanofi Genzyme); and compensation for serving as a journal editor, associate editor, or member of an editorial advisory board (Multiple Sclerosis Journal: Experimental, Translational and Clinical). EJF: Consulting and/or speaking fees, and grant/research support (Acorda, Bayer, Biogen, Chugai, Eli Lilly, EMD Serono, Genentech, Novartis, Opexa, Roche, Sanofi, Sanofi Genzyme, and Teva Pharmaceuticals). EH: Honoraria and grant support (Actelion, Biogen, Merck Serono, Novartis, Receptos, Roche, Sanofi Genzyme, and Teva) and is supported by Ministry of Education of Czech Republic. H-PH: Consulting and/or speaking fees (Bayer, Biogen, CSL Behring, Grifols, Merck Serono, Novartis, Roche, and Sanofi Genzyme). PM: Consulting and/or speaking fees (Biogen, Novartis, Sanofi-Aventis, and Teva Pharmaceuticals). KWS: Consulting and/or speaking fees (Biogen, Merck, Novartis, Roche, Sanofi Genzyme, and Synthon). PV: Consulting and/or speaking fees, and research support (Almirall, Bayer, Biogen, GlaxoSmithKline, Merck Serono, Novartis, Sanofi Genzyme, and Teva). BVW: Received research and travel grants, honoraria for MS-expert advice, and speakers fees (Bayer-Schering, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and Teva). DHM, KT, and CER: Employees of Sanofi Genzyme. XM: Consulting and/or speaking fees (Almirall, Bayer, Biogen, EMD, Genentech, Geneuro, Merck, Neurotec, Novartis, Roche, Sanofi, Sanofi Genzyme, and Teva Pharmaceuticals). | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.title | Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). | - |
dc.type | Journal Contribution | - |
local.bibliographicCitation.conferencedate | SEP 14-17, 2016 | - |
local.bibliographicCitation.conferencename | 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) | - |
local.bibliographicCitation.conferenceplace | London, ENGLAND | - |
dc.identifier.epage | 76 | - |
dc.identifier.spage | 75 | - |
dc.identifier.volume | 22 | - |
local.format.pages | 2 | - |
local.bibliographicCitation.jcat | M | - |
dc.description.notes | [Coles, A. J.] Univ Cambridge, Sch Med, Cambridge, England. [Boyko, A. N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, A. N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [Cohen, J. A.] Cleveland Clin, Cleveland, OH 44106 USA. [De Seze, J.] Univ Strasbourg, Strasbourg, France. [Fox, E. J.] Cent Texas Neurol Consultants, Round Rock, TX USA. [Havrdova, E.] Charles Univ Prague, Med Fac 1, Prague, Czech Republic. [Hartung, H. -P.] Heinrich Heine Univ, Dusseldorf, Germany. [Inshasi, J. S.] Rashid Hosp, Dubai, U Arab Emirates. [Inshasi, J. S.] Dubai Med Coll, Dubai, U Arab Emirates. [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia. [Selmaj, K. W.] Med Univ Lodz, Lodz, Poland. [Vermersch, P.] Univ Lille Nord France, Lille, France. [Van Wijmeersch, B.] Univ Hasselt, Hasselt, Belgium. [Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.] Sanofi Genzyme, Cambridge, MA USA. [Montalban, X.] MS Ctr Catalonia, Barcelona, Spain. | - |
local.publisher.place | LONDON | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
local.bibliographicCitation.artnr | 213 | - |
dc.identifier.isi | 000383267200122 | - |
item.fulltext | With Fulltext | - |
item.contributor | Coles, A. J. | - |
item.contributor | Boyko, A. N. | - |
item.contributor | Cohen, J. A. | - |
item.contributor | De Seze, J. | - |
item.contributor | Fox, E. J. | - |
item.contributor | Havrdova, E. | - |
item.contributor | Hartung, H. -P. | - |
item.contributor | Inshasi, J. S. | - |
item.contributor | McCombe, P. | - |
item.contributor | Selmaj, K. W. | - |
item.contributor | Vermersch, P. | - |
item.contributor | VAN WIJMEERSCH, Bart | - |
item.contributor | Margolin, D. H. | - |
item.contributor | Thangavelu, K. | - |
item.contributor | Rodriguez, C. E. | - |
item.contributor | Montalban, X. | - |
item.fullcitation | Coles, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E. & Montalban, X. (2016) Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. In: MULTIPLE SCLEROSIS JOURNAL, 22, p. 75-76 (Art N° 213). | - |
item.accessRights | Open Access | - |
crisitem.journal.issn | 1352-4585 | - |
crisitem.journal.eissn | 1477-0970 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Alemtuzumab provides durable improvements in clinical outcomes in treatment.pdf | Peer-reviewed author version | 447.95 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
10
checked on Oct 14, 2024
Page view(s)
116
checked on Sep 7, 2022
Download(s)
4
checked on Sep 7, 2022
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.